Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsAztreonamLD 1000mg IV, then 500mg IV Q12HAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
435751.7-2.96-845-600.5-1.012.7-4040 (low flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Cunha B. Aztreonam. Urology 1993; 41(3), 249-58.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
  • Sattler F, Schramm M, Swabb E. Safety of aztreonam and SQ 26,992 in elderly patients with renal insufficiency. Reviews of infectious diseases 2012; 7( Suppl 4), S622-7.
  • Nagasaka H, Inagaki O, Nakagawa K et al. Pharmacokinetics of Aztreonam on Hemodialysis. Japanese Journal of Antibiotics 1990; 43(2), 345-54.